Log in

NASDAQ:TTOO - T2 Biosystems Stock Price, Forecast & News

$0.65
-0.02 (-3.00 %)
(As of 03/27/2020 04:00 PM ET)
Today's Range
$0.65
Now: $0.65
$0.75
50-Day Range
$0.28
MA: $0.68
$1.14
52-Week Range
$0.24
Now: $0.65
$3.28
Volume14.77 million shs
Average Volume9.38 million shs
Market Capitalization$30.15 million
P/E RatioN/A
Dividend YieldN/A
Beta1.44
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. It provides T2 Magnetic Resonance platform that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, and urine. The company also offers T2Dx, a bench-top instrument for detecting pathogens associated with sepsis and Lyme disease, and other applications, as well as T2Candida panel that identifies the species of Candida, a fungal pathogen known to cause sepsis directly from whole blood. In addition, it is developing Candida Auris, a multi-drug resistant pathogen; T2Bacteria, a multiplex diagnostic panel that detects various bacterial pathogens associated with sepsis; and T2Lyme for the detection of various strains of Lyme disease-causing bacteria. The company has collaboration agreements with Canon U.S. Life Sciences, Inc. to develop a diagnostic test panel to detect Lyme disease; and Allergan Sales, LLC to develop detection diagnostic test panel that adds one additional bacteria species to the existing T2Bacteria product candidate, as well as for testing drug resistance directly in whole blood. T2 Biosystems, Inc. was founded in 2006 and is headquartered in Lexington, Massachusetts.
Read More
T2 Biosystems logo

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TTOO
CUSIPN/A
Phone781-761-4646

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$8.34 million
Book Value($0.73) per share

Profitability

Net Income$-59,010,000.00
Net Margins-706.01%

Miscellaneous

Employees153
Market Cap$30.15 million
Next Earnings Date5/7/2020 (Estimated)
OptionableOptionable

Receive TTOO News and Ratings via Email

Sign-up to receive the latest news and ratings for TTOO and its competitors with MarketBeat's FREE daily newsletter.


T2 Biosystems (NASDAQ:TTOO) Frequently Asked Questions

How has T2 Biosystems' stock been impacted by COVID-19 (Coronavirus)?

T2 Biosystems' stock was trading at $0.4950 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, TTOO stock has increased by 30.5% and is now trading at $0.6460. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of T2 Biosystems?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for T2 Biosystems in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for T2 Biosystems.

When is T2 Biosystems' next earnings date?

T2 Biosystems is scheduled to release its next quarterly earnings announcement on Thursday, May 7th 2020. View our earnings forecast for T2 Biosystems.

How were T2 Biosystems' earnings last quarter?

T2 Biosystems Inc (NASDAQ:TTOO) posted its quarterly earnings data on Monday, February, 24th. The medical equipment provider reported ($0.29) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.27) by $0.02. The medical equipment provider had revenue of $3.10 million for the quarter. T2 Biosystems had a negative net margin of 706.01% and a negative return on equity of 1,263.80%. View T2 Biosystems' earnings history.

What guidance has T2 Biosystems issued on next quarter's earnings?

T2 Biosystems issued an update on its first quarter 2020 After-Hours earnings guidance on Tuesday, March, 24th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $2.2-2.6 million, compared to the consensus revenue estimate of $3.11 million.

What price target have analysts set for TTOO?

6 analysts have issued 12-month target prices for T2 Biosystems' shares. Their forecasts range from $0.40 to $10.00. On average, they expect T2 Biosystems' stock price to reach $5.73 in the next year. This suggests a possible upside of 787.5% from the stock's current price. View analysts' price targets for T2 Biosystems.

What are Wall Street analysts saying about T2 Biosystems stock?

Here are some recent quotes from research analysts about T2 Biosystems stock:
  • 1. According to Zacks Investment Research, "T2 Biosystems, Inc. is an in vitro diagnostics company. It has developed a technology platform that is designed to offer a rapid, sensitive and simple alternative to existing diagnostic methodologies. The Company uses its T2 Magnetic Resonance platform, or T2MR, that enables rapid detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets. It operates primarily in the United States. T2 Biosystems, Inc. is headquartered in Lexington, Massachusetts. " (3/4/2020)
  • 2. HC Wainwright analysts commented, "We do not currently have a price target on TTOO shares. Risks include, but are not limited to: (1) failure of to achieve commercial success due to market size, penetration rate, and/or competition; (2) failure to secure regulatory approval for T2Lyme; and (3) potential dilution risk." (8/7/2019)

Has T2 Biosystems been receiving favorable news coverage?

Headlines about TTOO stock have been trending negative on Saturday, according to InfoTrie Sentiment. The research group identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. T2 Biosystems earned a coverage optimism score of -2.0 on InfoTrie's scale. They also gave news coverage about the medical equipment provider a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an impact on the stock's share price in the near future. View the latest news aboutT2 Biosystems.

Are investors shorting T2 Biosystems?

T2 Biosystems saw a decrease in short interest during the month of March. As of March 13th, there was short interest totaling 4,822,000 shares, a decrease of 14.8% from the February 27th total of 5,660,000 shares. Based on an average daily volume of 17,767,200 shares, the short-interest ratio is currently 0.3 days. Currently, 13.7% of the company's stock are short sold. View T2 Biosystems' Current Options Chain.

Who are some of T2 Biosystems' key competitors?

What other stocks do shareholders of T2 Biosystems own?

Who are T2 Biosystems' key executives?

T2 Biosystems' management team includes the following people:
  • Mr. John P. McDonough, CEO, Pres & Director (Age 59)
  • Prof. Michael J. Cima, Co-Founder & Director (Age 59)
  • Dr. Thomas J. Lowery Jr., Chief Scientific Officer (Age 40)
  • Dr. Tyler E. Jacks, Co-Founder (Age 58)
  • Mr. Lee Josephson, Co-Founder & Member of Scientific Advisory Board

What is T2 Biosystems' stock symbol?

T2 Biosystems trades on the NASDAQ under the ticker symbol "TTOO."

Who are T2 Biosystems' major shareholders?

T2 Biosystems' stock is owned by a variety of retail and institutional investors. Top institutional investors include Gagnon Securities LLC (0.81%), Levin Capital Strategies L.P. (0.29%), Virtu Financial LLC (0.19%), State Street Corp (0.13%), Oxford Asset Management LLP (0.12%) and Tower Research Capital LLC TRC (0.07%). Company insiders that own T2 Biosystems stock include Alec Barclay, David B Elsbree, John Mcdonough, Michael J Cima, Michael Terrence Gibbs, Stanley Lapidus and Thomas J Lowery. View institutional ownership trends for T2 Biosystems.

Which institutional investors are selling T2 Biosystems stock?

TTOO stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, and Gagnon Securities LLC. Company insiders that have sold T2 Biosystems company stock in the last year include Alec Barclay, David B Elsbree, John Mcdonough, Michael J Cima, and Thomas J Lowery. View insider buying and selling activity for T2 Biosystems.

Which institutional investors are buying T2 Biosystems stock?

TTOO stock was purchased by a variety of institutional investors in the last quarter, including Levin Capital Strategies L.P., Virtu Financial LLC, Oxford Asset Management LLP, and Tower Research Capital LLC TRC. View insider buying and selling activity for T2 Biosystems.

How do I buy shares of T2 Biosystems?

Shares of TTOO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is T2 Biosystems' stock price today?

One share of TTOO stock can currently be purchased for approximately $0.65.

How big of a company is T2 Biosystems?

T2 Biosystems has a market capitalization of $30.15 million and generates $8.34 million in revenue each year. The medical equipment provider earns $-59,010,000.00 in net income (profit) each year or ($1.30) on an earnings per share basis. T2 Biosystems employs 153 workers across the globe. View additional information about T2 Biosystems.

What is T2 Biosystems' official website?

The official website for T2 Biosystems is http://www.t2biosystems.com/.

How can I contact T2 Biosystems?

T2 Biosystems' mailing address is 101 HARTWELL AVENUE, LEXINGTON MA, 02421. The medical equipment provider can be reached via phone at 781-761-4646 or via email at [email protected]


MarketBeat Community Rating for T2 Biosystems (NASDAQ TTOO)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  366 (Vote Outperform)
Underperform Votes:  292 (Vote Underperform)
Total Votes:  658
MarketBeat's community ratings are surveys of what our community members think about T2 Biosystems and other stocks. Vote "Outperform" if you believe TTOO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TTOO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel